EGFR and neoplasm: There was no difference between the new agent and erlotinib alone in terms of inhibiting the proliferation of cancer cells and suppressing EGFR signaling in vitro and in vivo but by injecting NUFS-sErt into the brain ventricle, a significant tumor growth inhibition was observed in an intracranial xenograft model, indicating a possible alternative treatment for patients with central nervous system metastases [154].